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Context: Consensus regarding diagnosis and management of osteoporosis in premenopausal 
women (PW) is still lacking due to few studies carried out in this population.
Design: The European Calcified Tissue Society and the International Osteoporosis Foundation 
convened a working group to produce an updated review of literature published after 2017 on 
this topic.
Results: Fragility fractures in PW are rare and mostly due to secondary osteoporosis (ie, in 
presence of an underlying disease such as hormonal, inflammatory, or digestive disorders). In 
absence of another disorder, low bone mineral density (BMD) together with fragility fractures 
qualifies as idiopathic osteoporosis. In contrast, low BMD alone does not necessarily represent 
osteoporosis in absence of bone microarchitectural abnormalities. BMD increases in PW with 
osteoporosis when the underlying disease is treated. For example, in celiac disease, an increase 
of 9% in radius trabecular volumetric density was achieved after 1 year of gluten-free diet, 
while anti-tumor necrosis factor alpha improved BMD in PW with inflammatory bowel diseases. 
In amenorrhea, including anorexia nervosa, appropriately delivered estrogen replacement 
therapy can also improve BMD. Alternatively, antiresorptive or anabolic therapy has been shown 
to improve BMD in a variety of conditions, the range of improvement (3%-16%) depending on 
skeletal site and the nature of the secondary cause. No studies were powered to demonstrate 
fracture reduction. The effects of bisphosphonates in childbearing women have been scantly 
studied and caution is needed.
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Conclusion: The majority of PW with osteoporosis have an underlying disease. Specific therapy 
of these diseases, as well as antiresorptive and anabolic drugs, improve BMD, but without 
evidence of fracture reduction. (J Clin Endocrinol Metab 105: 1–20, 2020)
Key Words:  premenopausal women, osteoporosis, fracture, secondary osteoporosis, pregnancy, 
antiresorptive therapy
The epidemiology of osteoporosis and fracture rate in premenopausal women is uncertain. The prevalence 
of osteoporosis in premenopausal women varies from 
0.5% to 50% depending on the population studied, the 
definition of osteoporosis used, and the referral center 
involved (1,2). A  European study in premenopausal 
women (mean age 34.8 ± 0.5) from the general popu-
lation found no subjects with osteoporosis (defined 
as a T-score  ≤ −2.5  SD) and 10.6% with osteopenia 
(T-score  > −2.5 and  ≤ −1.0  SD) (3). However such 
data can be misleading since a low areal bone mineral 
density (aBMD) alone at a young age may reflect a rela-
tively thinner skeleton, for instance in a constitutionally 
lean person, but with normal volumetric bone material 
density (BMD) and no alterations of microstructure (ie, 
not necessarily more fragile bones). In contrast, in pre-
menopausal women with known causes of secondary 
osteoporosis, the prevalence of low bone mass (defined 
as Z-score  ≤ −2 SD) was recently reported as 17.3% in 
patients affected by systemic lupus erythematosus (4), 
7.3% in rheumatoid arthritis (5), 44.5% in Cushing dis-
eases (6), 35% in HIV (7), and 45% in cystic fibrosis (8), 
and these disorders are associated with an increased risk 
of fragility fractures.
A premenopausal woman with a prior fracture has 
a 35% to 75% higher risk of having a fracture in her 
postmenopausal years than a premenopausal woman 
without fracture (9). Therefore, early diagnosis and 
management may be beneficial, although currently no 
studies have investigated this strategy with respect to 
reducing fractures later in life (10,11). Few reviews on 
osteoporosis in premenopausal women have been pub-
lished (1,2,10,12-15), with the latest narrative review 
and guidance paper dating from 2017 (16,17). The pur-
pose of the present review is to provide an update on 
literature published after 2017 regarding diagnosis and 
management of osteoporosis in premenopausal women, 
excluding children and adolescents.
Search Strategy
The European Calcified Tissue Society (ECTS) and the 
International Osteoporosis Foundation (IOF) formed 
a working group to carry out a comprehensive review 
of existing literature by means of a search in PubMed 
for English-language literature published from January 
2017 to July 2019 using the following search terms in 
the title, without exclusion criteria: “premenopausal,” 
“osteoporosis,” “fracture,” “pregnancy and lactation in-
duced osteoporosis,” “secondary osteoporosis,” “anor-
exia/eating disorders,” “vitamin D,” “bisphosphonates,” 
“teriparatide,” “denosumab,” and “calcium.”
Among the 248 papers identified, we considered as 
high-quality papers those reporting on randomized con-
trolled trials (RCTs); we also included observational 
studies, case series, meta-analysis, and reviews if it was 
clearly stated that premenopausal women were en-
rolled. At the end, a total of 139 papers were included 
in this review.
Factors Affecting Peak Bone Mass and 
Early Fracture Risk
The BMD of premenopausal women depends primarily 
on their bone accrual during childhood and adolescence 
as the final peak bone mass is reached around the age of 
20 years, depending on the skeletal site.
Although 40% to 80% of the variation in BMD 
and bone microarchitecture is genetically determined 
(18,19), a myriad of diseases and lifestyle factors, even 
from very early life (20), may influence physiological 
bone accrual resulting in a lower bone mass in adult-
hood, as recently reviewed (21).
Lean body mass is a significant predictor of aBMD 
at all skeletal sites, accounting for 7% to 26 % of the 
variance (P = 0.043-0.001) (22), after adjusting for age, 
and bone-specific physical activity. The association be-
tween lean mass and bone accrual might also be due 
to other factors, such as nutrition, hormones, and gen-
etic factors that have independent effects on muscle and 
bone. Moreover, muscle power has been shown to be a 
positive determinant of femoral neck (FN) and total hip 
BMD, FN cross-sectional area, FN cross-sectional mo-
ment of inertia and FN Z-score in 148 women between 
18 and 35 years (23). Thus, it can be speculated that 
exercise, which improves lean mass and muscle power, 
has a positive effect on peak bone mass accrual, as it has 
been shown in previous studies (24-27).
Sexual development and function is crucial for 
bone mass accrual. A recent Canadian cross-sectional, 
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population-based study of 499 menstruating women 
with a BMD measurement after attaining peak bone 
mass, showed that 18% of lumbar spine (LS) BMD 
was attributed to positive contributions of current body 
mass index (BMI) and height, with negative influences 
from previous history of amenorrhea and androgen ex-
cess. Approximately 20% of the variation in FN BMD 
was explained by current BMI and height (positive ef-
fect) and age at menarche (negative effect) (28), as also 
reported previously (29). A  specific group of women, 
who may experience menstrual dysfunction, are those 
actively involved in sports at the competitive level. 
When this is accompanied by a low caloric intake and a 
low bone density, it constitutes the so-called female ath-
lete triad. Components of the triad are interrelated: if 
one is identified, the others should be actively evaluated 
as suggested by the 2017 update consensus on issues in 
female athletes (30).
Oral contraceptives
Although hormonal contraception during adoles-
cence was considered a controversial issue regarding 
bone health in the past, the latest meta-analysis, 
including 1535 adolescents, showed that combined 
hormonal contraceptives resulted in a weighted mean 
LS BMD difference of −0.02  g/cm2 (95% confidence 
interval [CI] −0.05 to 0.00, P = 0.04) compared to non-
users over a 12-month period (31). The same difference 
in BMD was seen over 24 months. However a recent 
retrospective case control study including 12 970 pre-
menopausal women reported a significant decrease of 
fracture risk with the use of combined oral contracep-
tives. The magnitude of the risk reduction was larger 
with increased duration of combined oral contraceptive 
use (32). Depot medroxyprogesterone acetate (DMPA) 
is a safe injectable contraceptive but most users be-
come amenorrheic within 1  year due to suppression 
of gonadotropin secretion and consecutive inhibition 
of ovarian estradiol production. In young women (less 
than 30 years old) with long-term exposure to DMPA 
(≥10 prescriptions), a higher fracture risk was identified 
(odds ratio [OR] 3.04, 95 % CI 1.36 to 6.81). Similar 
findings were reported for women in their late repro-
ductive years with past use of DMPA (OR 1.72, 95 % 
CI 1.13 to 2.63) (33).
Lifestyle habits
In 2016, the National Osteoporosis Foundation pub-
lished a position statement on peak bone mass and 
lifestyle, as lifestyle habits may contribute to 20% to 
40% of the mean variance of adult peak bone mass. The 
best available evidence (grade A) exists on the positive 
effects of calcium intake and physical activity (34). In 
addition, protein intake has been shown to enhance the 
effect of physical activity in the young, in particular at 
weight-bearing sites (35). It should be noted that there 
are gene-environment interactions in the skeletal re-
sponse to nutrition and exercise during growth (36). In 
particular, a model, which takes into account the early 
influence of vitamin D receptor polymorphisms, cal-
cium intake, and puberty on areal BMD gain, has been 
proposed to explain the relation between these geno-
types and peak bone mass (37,38), but further longitu-
dinal studies are needed to substantiate this hypothesis. 
Vitamin D sufficiency promotes normal bone mineral-
ization necessary to obtain an optimal peak bone mass. 
At the age of 16 years, 25-hydroxyvitamin D (25(OH)
D) ≥ 50 nmol/L has been associated with a higher total 
body aBMD, with a lower porosity at the radius and 
with a higher trabecular number at the tibia as shown 
by high-resolution peripheral quantitative computed 
tomography (HR-pQCT) (39). However, data from the 
United Kingdom National Diet and Nutrition Survey 
showed that 22% of adolescents aged 11 to 18 years 
had 25(OH)D < 25 nmol/L (40). Measuring 25(OH) D 
in this population, during winter season, increased this 
percentage up to 40% (40).
The corollary to the major influence of hormonal and 
lifestyle habits on peak bone mass acquisition is that 
childhood disorder affecting pubertal maturation, BMI, 
nutritional intake, or exercise capacity, among others, 
will likely have long-lasting repercussions on BMD and 
fracture risk. A good example is type 1 diabetes mellitus, 
which is usually diagnosed at a young age, whereby 
several alterations detrimental to bone health, such as 
glucose toxicity and deficit in the insulin/insulin-like 
growth factor 1 axis, lead to a lifelong fracture risk ap-
proximately 6-fold higher than in the nondiabetic popu-
lation (41).
Diagnosis
For postmenopausal women the diagnosis of osteopor-
osis is based on the World Health Organization oper-
ational definition of a dual X-ray absorptiometry (DXA) 
of bone with a T-score below or equal to −2.5 standard 
deviation (SD). For subjects younger than 40 years old, 
the International Society for Clinical Densitometry pro-
posed us BMD Z-scores below or equal to −2 SD (com-
parison to age and sex matched value) to define low 
bone mass, which is a value below the expected range 
for age (42).
The IOF also defines low bone mass in the young as 
Z-scores below −2 SD, however, only before 20  years 
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of age. Thereafter, they kept the same definition as in 
postmenopausal women, namely, a T-score  ≤ −2.5 
SD  for individuals older than 20 years and in the ab-
sence of delayed puberty (1).
Such BMD threshold differences in the definition of 
premenopausal osteoporosis may result in confounding 
epidemiological data in the literature. Nevertheless, 
vertebral and/or multiple fragility fractures with low 
BMD are a hallmark of osteoporosis for both soci-
eties. Hence, for premenopausal women with low 
BMD (ie, Z-score  ≤ −2 SD or T-score  ≤ −2.5 SD) but 
without fractures, a diagnosis of low peak bone mass 
vs osteoporosis may be difficult to ascertain. It is im-
portant to remember that the pathophysiology of osteo-
porosis involves not only a deficit in bone quantity (ie, 
BMD) but also microarchitectural alterations, which in 
postmenopausal osteoporosis result from increased bone 
resorption and imbalanced bone remodeling, whereas in 
premenopausal women they may also result from dis-
turbances in peak bone mass acquisition. Indeed deficits 
in bone mass, structure, and strength (stiffness) have 
ben reported using quantitative computed tomography 
in younger patients with low bone mass and without 
fracture, as well as in patients with idiopathic osteo-
porosis with fractures (43). Further studies are there-
fore needed to define the utility of specific radiological 
and/or biochemical tools that may help to differentiate 
true osteoporosis from physiologically low bone mass 
in the young.
In practice, several steps are necessary for a correct 
diagnosis of premenopausal osteoporosis, also taking 
into consideration that current guidelines are based 
on postmenopausal osteoporosis and do not generally 
recommend DXA screening in premenopausal women 
(44). After a detailed medical history and a DXA meas-
urement, including, if possible, a vertebral fracture as-
sessment, an adapted biochemical evaluation is needed 
to ascertain causes of secondary osteoporosis, as pro-
posed by IOF in 2012 (1). A genetic evaluation is sug-
gested when there is a strong suspicion of a heritable 
component based on both family history and/or add-
itional clinical features (syndromes) suggestive of an 
underlying monogenetic bone disorder (1). In absence 
of this, a diagnosis of idiopathic osteoporosis can me 
made.
Identifying Patients at High Fracture Risk
Once a diagnosis of osteoporosis has been made, the 
next step is to evaluate fracture risk. Although clas-
sical risk factors should be taken into account, it is im-
portant to note that the FRAX® algorithm is validated 
for individuals older than 40 years only. Premenopausal 
women with recent major fragility fractures (hip, verte-
bral, proximal humerus, and distal forearm fractures) 
should be considered at high risk for further fractures 
in the short to medium term, and further assessment 
is recommended. For example, in a 6-year follow-up 
study, approximately 25% of a cohort of 107 patients 
affected by pregnancy- and lactation-associated osteo-
porosis (PLAO) had a new fracture, and among individ-
uals who had a new pregnancy, 20% sustained a new 
fracture (45).
Premenopausal women without a fracture often 
undergo a DXA because of existing risk factors for 
bone fragility. For example, in the case of celiac disease, 
a Canadian position statement suggests performing 
DXA measurement at the time of first diagnosis of the 
underlying disease, which is often at premenopausal ages 
(46). In this case, as in most cases of secondary osteo-
porosis, the fracture risk is not only related to BMD and 
the classical risk factors, but also to the specific char-
acteristics of the underlying disease and its treatment, 
as also recently illustrated for diabetes (47). In a small 
prospective study investigating the performance of bone 
turnover markers in relation to distal radius fractures in 
premenopausal women, osteocalcin, propeptide of type 
I  procollagen (PINP), bone alkaline phosphatase, and 
C-terminal telopeptide of type 1 collagen all showed 
only moderate prediction (48). Bone turnover markers 
were evaluated 3 months after the fracture, which may 
still be influenced by the late phase of fracture healing. 
On another side, in healthy premenopausal women in 
the transition to menopause (aged 44-57) followed for 
5  years, higher PINP and C-terminal telopeptide con-
centrations predicted lower BMD, suggesting that bone 
turnover markers could have potential use in identifying 
women at higher risk of rapid bone loss (49). Yet an-
other recent study suggests that single bone turnover 
markers may not be able to identify bone loss for an 
individual patient (50). As previously mentioned re-
garding their potential utility in the diagnosis of osteo-
porosis, there are more sophisticated imaging modalities 
able to assess bone microarchitecture which might also 
help in the identification of patients at high fracture risk. 
Although longitudinal studies on the role of HR-pQCT 
in predicting fracture risk in premenopausal women are 
not available, new cross-sectional data warrant atten-
tion. Premenopausal women with distal radius fracture 
and mean age 29.8 ± 8.0  years showed no differences 
in aBMD at the radius, FN and LS when compared to 
subjects of the same age, race, BMI, caffeine intake, al-
cohol consumption, and physical activity not having ex-
perienced fractures (51). However, HR-pQCT revealed 
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impaired trabecular and cortical parameters in women 
having sustained fractures. The addition of individual 
trabecular segmentation to HR-pQCT images helped to 
further identify women with radius fractures. The area 
under the curve for discriminating patients with fracture 
from women without fracture was 0.74 for the propor-
tion of axially aligned trabeculae (which is an individual 
trabecular segmentation parameter at radius), whereas 
the area under the curve values for classical parameters 
such as aBMD and trabecular density were lower (51). 
The same trend was reported for tibia measurements 
(51). Thus, although HR-pQCT parameters are able 
to capture a difference in bone microstructure between 
women with and without fracture, independently of 
BMD, more sophisticated analyses may be necessary to 
better characterize premenopausal women at increased 
risk of fracture.
Causes of Secondary Osteoporosis
Osteoporosis in premenopausal women is more fre-
quently caused by underlying diseases, with the more 
recent publications summarized in Table 1 (for a more 
complete list of diseases associated with secondary 
osteoporosis, see Ferrari et al (1)). In case series and 
observational studies, which included both premeno-
pausal women and young men with osteoporosis, the 
majority of the subjects were found to have a cause 
of secondary osteoporosis at a range varying from 
50% to 90% depending on the setting and time of 
diagnosis (52-54). These include well-known condi-
tions with a negative impact on bone health, such as 
endocrine, inflammatory, neuromuscular, oncological, 
hematological, pulmonary, and gastrointestinal dis-
orders that are not specific for premenopausal age, but 
are often diagnosed before menopause (4-6,55-63). 
Other causes are HIV infection (7), hyperthyroidism 
(64), and thyroid stimulating hormone suppressive 
therapy (65). New data from HR-pQCT studies indi-
cate impaired trabecular and cortical compartments 
in the majority of these diseases, at times detected 
earlier than the impairment detected by DXA scan 
(Table  1). A  recent retrospective study, which com-
pared the characteristics of minimal trauma vs high 
trauma hip fractures in young patients, showed higher 
comorbidity rates in the former group. In addition, 
endocrinological and neurological diseases as well as 
nicotine intake were the most frequent. In particular, 
the number of patients with chronic endocrinological 
diseases was significantly higher in the minimal trauma 
group compared to the high trauma group (34.9% vs 
0%, P = 0.04) (66).
There is a limited number of heritable diseases with 
a known mutation causing secondary osteoporosis (67). 
Some of them are solely characterized by bone fragility, 
while the majority present with additional organ mani-
festations. Knowing the exact mutation(s) is of piv-
otal importance when a specific therapy is available. 
As an example, loss-of-function mutations in the gene 
encoding the tissue nonspecific alkaline phosphatase 
cause hypophosphatasia. The diagnosis is based on 
low alkaline phosphatase activity in serum and genetic 
testing that identifies the gene mutations, while bone 
fragility is present with a clinical heterogeneity due to 
more than 300 mutations of the gene discovered to 
date (68). Of interest, enzyme replacement therapy is 
now available for hypophosphatasia, and gene therapy 
is currently being investigated (68). However, for some 
other heritable diseases, the discovery of the exact gen-
etic defect has not led to a specific therapy yet. This ap-
plies to osteoporosis-pseudoglioma syndrome, which 
is a rare autosomal-recessive disorder with significant 
phenotypic variability caused by loss of function muta-
tions in the gene LRP5 characterized by bone fragility 
and blindness (69).
Anorexia nervosa
Anorexia nervosa (AN) is another condition as-
sociated with the development of osteoporosis in 
premenopausal women. The classical picture of an 
anorexic patient is a combination of psychiatric 
symptoms and somatic manifestations including low 
BMD, malnutrition, low body fat, and lean mass. 
Furthermore significant hormonal changes (hypo-
gonadism/amenorrhea, hypercortisolism, low testos-
terone levels, and resistance to growth hormone with 
low insulin growth factor [IGF]-1 levels) leads to a 
significantly lower BMD and higher fracture risk (70). 
A recent study applying new criteria for diagnosis of 
AN demonstrated low BMD in 78% of patients with 
the classic form of AN, in 82% of patients with low 
BMI without amenorrhea, and in 69% of patients 
with atypical AN (normal BMI but psychological 
symptoms of AN) (71). Thus, the deleterious effects 
of eating disorders on BMD appear to extend beyond 
our current knowledge of low BMI and amenorrhea-
induced detrimental effects on BMD (71). A  recent 
systematic review and meta-analysis showed that AN 
is associated with an increased likelihood of osteopor-
osis (OR = 12.59) and fractures (OR = 1.84) (70).
Importantly, a low BMI together with low BMD but 
without bone fragility or eating disorders, as seen in 
constitutionally lean subjects, should not be mistaken 
with AN-related osteoporosis (71).
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Table 1. Diseases associated with osteoporosis in premenopausal women, papers published since 2017
Diseases Patients Findings Summary Ref
Rheumatology
 SLE N = 173, mean age 
31 ± 8 years
Prevalence of BMD Z  < -2 SD was 17.3%. 4
N = 136, mean age 
38.8 ± 12.9 years
Multivariate linear regression analysis considering age, duration of 
disease, BMI, high-dose glucocorticoid use and current dose of 
glucocorticoids selected as independent variables, showed that 
disease duration was negatively associated with LS and FN BMD. 
BMI was positively associated with total hip and FN BMD.
55
N = 34274, 92.6% were 
female, mean age 
41 years, 
Multivariable HR for any fracture in SLE age  < 50 compared to 
age and sex matched controls was: HR 2.28 (1.90–2.74); HR 
adjusted for glucocorticoids use 1.74 (1.40–2.15), HR adjusted for 
comorbidities 1.97 (1.61–2.41). All P < 0.01.
56
 RA N = 96, mean age 
36.9 ± 5.3 years
Higher rate of osteoporosis in RA patients compared to age matched 
controls was found. In RA patients, the prevalence of osteoporosis 
at radius was 9.38%, at hip 6.25% and at LS 7.29%.  
Stepwise linear regression analysis showed that total lean mass was 
the best, independent significant predictor of BMD at all different 
sites, followed by the score of the disease severity (DAS28) at 
femoral sites.
5
Endocrine
 Cushing’s 
disease
N = 37, 28 
premenopausal, mean 
age 30.7 ± 11.7 years
44.5% of patients had osteoporosis, 35.1% had morphometric 
vertebral fractures.
6
 PHPT N = 54, mean age 
40.5 ± 6.8 years
18.5% of patients had osteoporosis at any site. T-score BMD: at distal 
third radius was -1.1 ± 1.2, at LS 1.7 ± 1.3, at FN 1.5 ± 1.2.
57
 DM type 1 N = 35925 (male and 
female), mean age 
18–50 years
This meta-analysis showed a RR for any fracture of 1.85 (95%CI 
1.5–2.3, P < 0.001) in diabetic females compared to controls.
58
Gastroenterology/Malnutrition
 Celiac disease N = 563 premenopausal 
women and men, age 
NA
 In this meta-analysis, the pooled prevalence of osteoporosis was 
14.4% (95% CI: 9–20.5%) and osteopenia was 39.6% (31.1–
48.8%) respectively.
59
 IBD N = 59, mean age 
23.1 ± 5.8 years
IBD patients had a nearly 10% lower aBMD at radius, spine 
and hip and alterations in trabecular and cortical bone 
microarchitecture. Higher disease activity scores had a negative 
impact on aBMD and vBMD, as well as microstructure. Prevalent 
fractures in IBD were not associated with aBMD (adjusted for 
age, sex and height), but with vBMD and with alterations of 
trabecular bone microarchitecture.
60
 Anorexia 
nervosa
N = 25, mean age 
27.5 years (23.8; 29.6) 
Lower bone mass and impaired bone microarchitecture in adult AN 
patients, compared to normal weight controls. The impairment 
of cortical thickness and estimated failure load were significantly 
more pronounced in the weight-bearing tibia, compared to the 
radius. 
61
Infectious disease
 PLWH N = 103, median age 35 
(25–45 years)
Osteoporosis was documented in 35% of females with HIV as 
compared to 8% of HIV-negative controls (P < 0.001). BMI was an 
independent predictor of osteoporosis, after adjusting for age and 
disease duration.
7
Genetic 
 Cystic fibrosis N = 42 patients (24 
females, mean age 
34.0 ± 8.4 years)
A BMD Z score below  − 2.0 SD or lower and at least one prevalent 
fragility fracture were found in 22 patients (52.4%) and 18 patients 
(45.2%), respectively.
8
N = 53, mean age 27.5 
(25.7–29.3)
20% of patients had osteoporosis at LS (T score  < -2,5 SD), and 35% 
at femoral sites.
62
 Thalassemia 
major
N = 82 patients, N = 39 
premenopausal 
women, mean age 
32 ± 6 years
15 patients had vertebral fractures, their mean LS BMD Z score 
was -2.66 SD and TBS 1.173, both significantly lower than in the 
patients without fractures. 
63
Abbreviations: BMD, bone mineral density; BMI, body mass index; DM, diabetes mellitus; FN, femoral neck; HR, hazard ratio; IBD, inflammatory 
bowel disease; LS, lumbar spine; N, number; NA, not available; PHPT, primary hyperparathyroidism; PLWH, people living with HIV; RA, rheumatoid 
arthritis; Ref, references; SLE, systemic lupus erythematosus; TBS, trabecular bone score.
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Lifestyle and dietary alterations
Lifestyle habits such as excessive alcohol consump-
tion, as well as heavy smoking, play an important role 
in the pathogenesis of bone fragility in premenopausal 
women. In a population of 789 premenopausal women 
aged 20 to 40 years, the OR for low LS BMD com-
pared to nonsmokers was 1.59 (95% CI 0.65 to 3.91) 
and 2.55 (95% CI 1.12 to 5.82) for subjects with to-
bacco use of less or more than 3 pack-years, respect-
ively (72).
Exclusion of animal meat protein intake (vegetar-
ianism) and even more so strict exclusion of any animal 
products (veganism) also carry an increased risk of 
osteoporosis. In a Bayesian meta-analysis, which in-
cluded 9 studies (2749 individuals; 1880 women with 
an average age ranging from 20 to 79  years), vege-
tarians showed a significant BMD reduction amount 
to 4% and an increase of 10% higher in fracture risk 
compared to nonvegetarians (73). However, in a re-
cent cross-sectional study, which included vegetarians 
and vegans with a mean age of approximately 30 years, 
83% of whom were female, calcaneus mineral density 
did not differ between vegetarians and nonvegetarians 
or between vegans and lacto-ovo vegetarians (74). Of 
note, the majority of vegetarians followed this diet for 
less than 5 years, and the authors used heel ultrasound, 
rather than DXA, which is the standard technique to 
measure bone density. In this study, protein, calcium, and 
vitamin D intakes of vegetarians were all lower than the 
respective intake of subjects whose diets included meat 
(P < 0.05) (74). Hypovitaminosis D, although more fre-
quent in vegetarians, is also an issue in meat-consuming 
premenopausal women (75), often in association with 
intestinal malabsorption. Osteomalacia should be dif-
ferentiated from osteoporosis when a low BMD is re-
ported. It should be noted, that malnutrition can also 
have a socioeconomical background, in particular in 
developing countries; a cross-sectional study conducted 
in among 430 women of reproductive age showed mal-
nutrition in 48.6% of the subjects (76).
Cancer-related and drug-induced osteoporosis
There is new evidence regarding the deleterious 
skeletal effects of drugs used only in women, in par-
ticular in the setting of breast cancer (77-80) (Table 2). 
Hence, adjuvant therapy, including chemotherapy and 
gonadotropin-releasing hormone (GnRH) analogs can 
induce secondary amenorrhea and premature meno-
pause. Moreover, tamoxifen, a selective estrogen re-
ceptor modulator, which has a protective role on bone 
in postmenopausal women, acts as an antiestrogen in 
premenopausal women and has been associated with 
a 75% increased risk of fracture in premenopausal 
patients with breast as compared to healthy controls 
(hazard ratio [HR] 1.75; 95% CI 1.25 to 2.48) (77).
In 2018, the Food and Drug Administration approved 
elagolix, an orally administered nonpeptide GnRH re-
ceptor antagonist, for endometriosis associated-pain 
management. Administered from 6 to a maximum of 
12 months, this drug was associated with BMD loss, es-
pecially with higher dosage (81,82) (Table 2). Recently, 
elagolix has been successfully used for uterine bleeding 
caused by fibroids, and also in this instance its use re-
sulted in decreased bone density which was mitigated 
when estradiol, 1  mg, and norethindrone acetate, 
0.5 mg, both taken once daily, were added (83).
Regarding cancer-related osteoporosis, both cancer 
itself, as well as its treatment, may induce bone loss. For 
example, autologous or allogeneic hematopoietic stem 
cell transplantation is the treatment of choice for most 
young patients with malignant hematological diseases; 
however, hematopoietic stem cell transplantation–re-
lated bone loss and increased fracture rate are among 
the main complications of this life-saving therapeutic 
intervention (84).
Glucocorticoid-induced osteoporosis in premeno-
pausal women is usually seen in patients with auto-
immune/inflammatory disorders and rheumatological 
diseases, themselves a cause of osteoporosis. Even if 
glucocorticoids exert multiple negative effects on bone 
health (85), they are also able to some extent to con-
trol the activity of the underlying disease, which in turn 
may exert some favorable effects on the preservation 
of bone mass/strength. These aspects have not been ad-
equately investigated in premenopausal women (86), 
but current management guidelines are discussed in the 
following text.
Idiopathic Osteoporosis
Idiopathic osteoporosis is defined as the occurrence of 
a low trauma fracture in the presence of low BMD (LS 
and or hip T-score  ≤ −2.5 SD) after excluding causes 
of secondary osteoporosis (1). The exact mechanisms 
underlying this disease remain incompletely understood 
but abnormalities in bone formation have been found 
on bone biopsies (87). Constitutionally lean subjects 
with low BMD, which is usually caused by low peak 
bone mass accrual related to both the genetic constitu-
tion, lifestyle, and environmental conditions (1) should 
not be considered affected by idiopathic osteoporosis, at 
least not in the absence of fragility fractures.
Examination of bone microstructure using HR-pQCT 
showed numerous similarities between a group of 23 
young patients with idiopathic osteoporosis defined 
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as prevalent fragility fractures and low BMD (without 
mutations in known osteoporosis-causing genes) and a 
group of 21 age- and sex-matched patients affected by 
mild to moderate osteogenesis imperfecta (type 1 and 
type IV). Both groups showed significant reduction in 
volumetric BMD and alterations in microstructural 
parameters at the distal radius and tibia compared to 
healthy controls. The only difference reported between 
osteogenesis imperfecta patients and patients with idio-
pathic osteoporosis was regarding geometry of the ra-
dius. No other differences were detected in HR-pQCT 
parameters at the radius and tibia (88).
In an attempt to better characterize idiopathic osteo-
porosis in young patients, next-generation sequencing 
was performed to screen for genes previously asso-
ciated with fracture or low BMD in a cohort of 123 
young adults with idiopathic osteoporosis. Novel vari-
ants were found in 11 subjects (regarding the following 
genes: COL1A2, WNT1, PLS3, and DKK1); however, 
there was no control group. In addition, previously re-
ported osteoporosis-causing variants in the LRP5 gene 
were found in 22 patients (89). In contrast, 45.5% of the 
patients studied carried no genetic variants in the exam-
ined genes. LRP5 variants have previously also been as-
sociated with idiopathic osteoporosis in men (90).
Pregnancy- and Lactation-Associated 
Osteoporosis
During pregnancy and lactation, the changes in cal-
cium metabolism lead to a transient bone loss, mainly 
at trabecular sites (91). Among the factors involved, 
parathyroid hormone related protein is secreted into 
the maternal circulation from the breasts tissue and pla-
centa and reaches its highest concentrations during the 
third trimester. After lactation, recovery of bone mass 
and strength normally occurs (92). In the long term, 
some studies showed that pregnancy and lactation 
Table 2. Drugs specifically used in women and their effects on bone, papers published since 2017
Drugs Patients
Study De-
sign Findings Summary Ref
Tamoxifen N = 3634; mean 
age 44.1 ± 5.1 
(18–50 years)
Retrospective 
study 
In patients with breast cancer treated with tamoxifen, a 
cumulative incidence of fractures was 6.3% compared to a 
cumulative incidence of 3.6% in the control group (P < 0.001). 
The risk of fracture was 75% higher for patients taking 
tamoxifen than that for healthy controls (HR 1.75; 95% CI 
1.25 to 2.48).
77
Tamoxifen N = 1761, 
mean age 
43.3 ± 6.1 years;  
age 41–50 years 
(72.8%) age 31-
40 years (22.3%) 
age 18-30 years 
(4.9%) 
Retrospective 
cohort
A positive association was found between breast cancer and 
fractures, adjusted HR = 2.39, (P < 0.001). HR was 2.58 
(P < 0.001) for women on tamoxifen versus healthy women, 
while HR for women without tamoxifen treatment versus 
healthy women was not statistically significant. After 10 years, 
women with fractures were 14.7% in the tamoxifen group vs 
12.9% in the group without tamoxifen. This difference was not 
statistically significant.
78
Tamoxifen 
plus ovarian 
function 
suppression 
(OFS)
N = 4690, age 
40 years
RCT SOFT 
and TEXT 
trial  
(8 years 
follow-up)
Percentage of patients with T-score of less than −2.5 SD was 
3.9% in the tamoxifen group, 7.2% in the combined 
tamoxifen–ovarian suppression group, and in 14.8% in the 
combined exemestane–ovarian suppression group.
79
Aromatase 
inhibitor (AI) 
plus OFS
N = 27, mean age 
43 years (range 
30.4 to 53.7)
Cross- 
sectional 
In patients with early breast cancer treated with OFS + AI for a 
median duration of 17 months, the cortical and trabecular 
volumetric BMD, assessed by HR-pQCT, was reduced compared 
to healthy age-matched controls. Also matrix mineral density 
was 1.56 SD (0.90 to 2.22) lower than controls.
80
Elagolix N = 872 in Elaris 
EM-I trial  
N = 817 in Elaris 
EM-II trial  
Mean age 31 years 
old
Double-blind, 
placebo-
controlled 
phase 
3 trials 
(6 months)
In Elaris EM-I, after 6 months, a decrease of more than 5% in 
LS BMD was reported in 3.8% of patients on a low dose of 
elagolix, compared to 20.9% of patients in the higher-dose 
elagolix group. In Elaris EM-II, the respective percentages were 
2.3% and 16.4%. 
81
Elagolix Extension Trial EM-
III and IV  
N = 569 women  
Mean age 32 years 
old
Double-blind, 
placebo 
controlled  
phase 3 trials  
(12 months)
After 12 months, in EM-III, the mean percentage age change 
from baseline in LS BMD was −0.63% for the low dose (Elaris 
EM-IV −1.10%) and −3.60% for the high dose (Elaris EM-IV 
3.91%). None of the patients had a Z-score below −2.0.
82
Abbreviations: BMD, bone mineral density; HR, hazard ratio; HR-pQCT, high-resolution peripheral quantitative computed tomography; N, number; 
RCT, randomized control trial; Ref, references.
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have a negative effect on bone health later in life, while 
other studies did not, as previously reviewed (92,93). 
Recently, in a study including 16 000 women followed 
for 16 years, parity and lactation were found to have a 
neutral effect on the long-term development of osteo-
porosis or fragility fractures (both clinical and morpho-
metric) (94).
Against this background, PLAO is characterized by 
fragility fractures occurring during pregnancy or lacta-
tion, and has been reported in approximately 210 cases 
in the literature but is much more common in reality 
(95, 96). The precise cause of this rare disorder remains 
unknown, in particular it remains unclear whether it is 
entirely caused by pregnancy itself in certain individuals 
and/or whether pregnancy reveals a status of prior bone 
fragility. A search for causes of secondary osteoporosis 
should be undertaken in women suffering a fracture 
during pregnancy and lactation.
The largest case-control study (102 PLAO subjects) 
identified various risk factors associated with this con-
dition. Performing fewer sports both before and after 
puberty, having had dental problems in childhood, 
and having suffered severe diseases and immobiliza-
tion during pregnancy were all risk factors significantly 
more frequent in PLAO subjects than in controls (95). 
The same risk factors were identified in a retrospective 
case-control study for transient osteoporosis of the hip 
during pregnancy, where immobilization during preg-
nancy was thrice more frequent in patients with tran-
sient osteoporosis of the hip compared to the control 
group (96). The latest and largest bone biopsy study 
in PLAO women where bone biopsies were performed 
12 months postpartum, aimed to assess the baseline state 
of bone remodeling. Transiliac bone biopsies in these 
women, showed a low bone turnover state, which was 
also confirmed by circulating bone turnover markers 
compared to patients affected by idiopathic osteopor-
osis, itself already a state of low bone formation (97). 
This study showed a dissociation between low PINP in 
PLAO compared to controls, while the concentration of 
C-terminal telopeptide of type 1 collagen did not signifi-
cantly differ (97).
These novel findings suggest the possibility of an 
underlying defect in osteoblast function taking into 
consideration the lower bone formation reported 
in PLAO women in the absence of lower osteoblast 
number (97).
In a small study of 7 PLAO patients, in addition 
to HR-pQCT, which revealed a reduction of the tra-
becular and cortical thicknesses, and DXA assessment, 
which revealed low BMD, a comprehensive genetic 
analysis was carried out. Using a custom-designed 
gene panel, a heterozygous missense variant in the 
LRP5 gene was reported in one of the patients, and 2 
women were diagnosed with osteogenesis imperfecta 
caused by heterozygous mutations in the COL1A2 and 
COL1A1 gene (98).
In summary, PLAO patients appeared to have the 
same risk factors for osteoporosis as those recognized 
for the development of postmenopausal osteoporosis 
and/or a possible osteoblast dysfunction revealed from 
bone biopsy and genetic analysis. Thus, it might be pos-
sible that a pre-existing bone impairment is present 
before pregnancy and that pregnancy is a trigger for 
its clinical development. However, further studies are 
needed to fully understand the exact mechanism beyond 
PLAO.
Management
Management of premenopausal osteoporosis is chal-
lenging due to a lack of robust evidence of how best 
to predict and decrease future fracture risk. Only few 
studies have assessed the effect of medical treatment and 
all were small-scale (Table 3).
A flow-chart for the overall management of premeno-
pausal women with osteoporosis and fragility fractures 
is shown in Fig. 1.
Nonpharmacological approaches
A 2-year RCT, which included 470 premenopausal 
women, aged 25 to 44  years, showed that educating 
young women concerning classical osteoporosis risk 
factors was associated with long-term improvements 
in osteoporosis preventive behavior. This change in be-
havior, followed-up for 10 years, led to an approximate 
2.4% attenuation of FN BMD loss in this population 
(99). This is of particular importance considering that 
a recent review on the knowledge, beliefs, and practices 
regarding osteoporosis among young adults revealed 
their lack of awareness about the disease (100).
Recently, new evidence on the effects of physical 
activity in premenopausal women has been published 
(101,102). Forty young women, aged 30 to 45 years and 
recently diagnosed with osteoporosis, were divided into 
4 groups with the following interventions over a period 
of 10 weeks: training (aerobic-resistance) group plus 
milk consumption (500 mL daily), only milk consump-
tion, only training and controls. This study showed that 
there were significant differences in hip and LS BMD in 
the training plus milk group with higher values com-
pared to training, milk consumers, and control groups 
(101). However, the small sample size and short dur-
ation of intervention limit a clinical translation of these 
findings.
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A RCT, including 206 premenopausal women diag-
nosed with breast cancer before the age of 55  years 
showed that an exercise intervention with a com-
bination of resistance training and aerobic exercise 
within 2  years of receiving adjuvant chemotherapy, 
prevented LS bone loss over a 12-month follow-up 
(LS BMD + 0.001 ± 0.005 g/cm2 treatment group vs 
−0.014  ±  0.005 g/cm2 control group, P  =  0.03) in 
women who did not suffer loss of lean mass during the 
study (102).
Although it is strongly advocated to quit smoking and 
alcohol consumption, no studies have demonstrated its 
effects on BMD/fracture risk in premenopausal women.
Pharmacological treatment
Calcium and vitamin  D. In the latest National 
Osteoporosis Foundation report, 93% of premeno-
pausal women (aged 19-30 years) had a dietary calcium 
intake below that suggested in the guidelines (34). When 
specifically asked about perceived adequate calcium 
intake, premenopausal women (aged 18-34 years) an-
swered that they were uncertain of what the benefits 
would be for their own age group but understood the 
importance for older ages (103). Vitamin D deficiency 
in premenopausal women was observed in various geo-
graphic areas, as recently reported by the latest ECTS 
position statement on vitamin D (75). Of particular 
concern, are the specific risk factors of hypovitaminosis 
D, such as covering of the body for traditional and/or 
religious reasons (104) and malabsorption syndromes, 
where higher rates of severe vitamin D insufficiency 
have been shown (105). Specific randomized trials with 
different dosages or schemes of calcium or vitamin D 
supplementation are lacking in this population in order 
to draw definite conclusions regarding the best treat-
ment strategy. Thus, in clinical practice, guidelines for 
the supplementation of calcium and vitamin D, with a 
target level of at least 50 nmol/L 25(OH) vitamin D in 
postmenopausal osteoporosis are usually implemented 
also for premenopausal patients with osteoporosis (44).
Figure 1. Flow chart on management and pharmacological treatment in premenopausal women with osteoporosis and fragility fracture  
(age >20 years old).
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Antiresorptive and bone-forming  therapy. Women 
at high fracture risk, such as patients with fragility 
fractures and low BMD, should be treated with bone 
drugs particularly if the underlying disease is difficult 
to control; however, fracture risk reduction with both 
antiresorptive and bone-forming treatment has not been 
demonstrated for premenopausal women with either 
secondary or idiopathic osteoporosis. Studies carried 
out so far usually were small-scale with short follow-
up periods and assessed BMD changes as the primary 
outcome. Several studies confirm that treatment of 
the underlying disease improves BMD in PW with 
secondary osteoporosis (Table  4) (106-110) but may 
not be sufficient.
Several recent publications, albeit few in the form of 
randomized trials, have shown improvement in BMD of 
premenopausal women using these drugs (111-115), as 
summarized in Table 3. This table also includes RCTs 
published after 2012, the time when the latest table 
summarizing treatments was published by IOF (1).
Two systematic reviews were recently published con-
cerning treatment of osteoporosis in men and women 
affected by cystic fibrosis (116) and by ß-thalassemia 
(117), and although only a few premenopausal 
women were included, both reviews concluded that 
bisphosphonates exerted a positive effect on BMD in 
these patients, but evidence regarding fracture reduction 
was lacking.
The latest meta-analysis in patients with inflamma-
tory bowel disease, which included 13 RCTs and 923 
male and female patients (age range 30-47 years) dem-
onstrated an improvement in BMD and a fracture re-
duction following bisphosphonate treatment; however, 
only 96 premenopausal women received an active 
bisphosphonate treatment, representing only 10% of 
the sample (118).
In patients with AN, weight gain is an important 
determinant for the recovering of BMD (119) and 
bisphosphonates are an option for increasing BMD 
(120). The latest review included 1 119 participants, 
and 10 of the 19 included studies were double-blind 
RCTs. However, the majority of the studies had a 
short follow-up period (ranging from 3 to 34 months), 
and the participants ages ranged from 11 to 37 years; 
thus, also patients who had not yet reached peak 
bone mass were included (120). Interestingly, in this 
review, the authors reported that administration of 
oral contraceptives did not significantly increase 
BMD in randomized controlled trials; however, trans-
dermal administration in adolescents was efficient in 
improving BMD, without data on fracture reduction 
(120). Another option such as low-dose testosterone 
did not change BMD but increased lean body mass in 
a 1-year follow-up study (121).
Glucocorticoid-induced osteoporosis. In 2012 IOF 
and ECTS published a joint paper on the management 
of glucocorticoid-induced osteoporosis and considered 
a premenopausal woman taking oral glucocorticoid for 
at least 3 months at risk for future fractures if she had 
a previous fracture (122). Clinical risk factors and the 
dose of prednisolone should also be taken into account 
for fracture risk assessment (122).
Furthermore, the latest American College of 
Rheumatology guidelines published in 2017 considered 
women <40 years of age with a fragility fracture at high 
risk for future fractures. DXA measurement is recom-
mended for patients at high and moderate risk, but also 
for patients receiving very high dosages of glucocortic-
oids or with other known risk factors for osteoporosis 
(123). Subjects with a hip or spine BMD Z score  < −3 
SD, or with a rapid bone loss (≥10% at the hip or spine 
over 1  year) and who have been treated with gluco-
corticoids for  ≥ 6 months at a daily dose  ≥ 7.5 mg are 
considered at moderate risk. Low-risk subjects are those 
treated with glucocorticoids without the previously 
mentioned conditions (123). We believe that due to 
the well-known detrimental effects of glucocorticoids, 
it may be a too conservative approach to not consider 
patients who have been receiving glucocorticoids for 
≥6 months at a daily dose ≥7.5 mg with a BMD Z score 
<−3 SD, or with a rapid bone loss, at high risk for frac-
ture. Until now, long-term follow-up studies designed 
to distinguish between high and moderate fracture risk 
in young premenopausal women, in this setting, are 
missing.
For low-risk patients the American College of 
Rheumatology recommend the administration of only 
calcium and vitamin D.  For moderate- and high-risk 
patients, oral bisphosphonates, in view of their safety 
and cost, are the preferred drugs (123). The IOF-ECTS 
GIO Guidelines Working Group suggested to start 
osteoporosis treatment for premenopausal women with 
fractures, while for women without fracture treatment 
decision should be based on clinical judgment, due to 
limited evidences (122).
Cancer-related osteoporosis. In the absence of guide-
lines for fractures prevention in premenopausal women 
with breast cancer and hormone ablation therapy, it has 
been suggested that bisphosphonates should be initiated 
in women with a Z score less than −2 SD. In women 
with a Z score equal to or less than −1 SD and a 5% to 
10% annual decrease in BMD, bisphosphonates are also 
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suggested together with calcium and vitamin D supple-
mentation (124).
In patients with early stage breast cancer under ad-
juvant chemotherapy, zoledronic acid 4  mg every 
3 months for 2 years was shown to prevent bone loss 
in a RCT in women who developed ovarian failure after 
adjuvant chemotherapy (125). Over a period of 5 years, 
in a study of 34 women (mean age 43 years), who were 
also treated with 4 mg intravenous zoledronic acid every 
3  months during 2  years, bone loss was prevented at 
the hip and significantly reduced at the spine compared 
to placebo-treated women, and BMD was maintained 
up to 3 years after bisphosphonate treatment was dis-
continued (126). Bone loss induced by ovarian suppres-
sion therapy (goserelin) and tamoxifen or anastrozole 
can also be prevented by zoledronic acid 4  mg every 
6  months for 3  years in premenopausal women with 
endocrine-sensitive early-stage breast cancer. Moreover, 
in this large study, disease-free survival was prolonged 
in patients receiving zoledronic acid (127).
Pregnancy-associated osteoporosis. For PLAO 
treatment, there are new data available from retro-
spective studies. In particular, a retrospective case-series 
of 12 patients diagnosed with PLAO at mean age of 
31 ± 5 years and treated with alendronate or zoledronic 
acid (n = 6), with a follow-up period of 6 months up to 
48 months, confirmed a gain in BMD and a decrease 
of bone turnover markers in each patient (128). The 
largest retrospective, multicenter study, including 52 
patients, with a mean of 3.8 ± 2 vertebral fractures, re-
ported that patients without any treatment had an an-
nual mean gain of LS BMD of 6.6% and 2.3% at the 
hip, whereas patients treated with bisphosphonates had 
an increase in LS BMD of 10.2% and 2.6% at the FN 
(129). Patients treated with teriparatide had an annual 
mean BMD gain of 14.9% at the LS and 5.6% at the 
FN. Approximately 19% had a new fracture during 
follow-up (36 months) regardless of treatment admin-
istered. Interestingly, the same magnitude of increase in 
LS BMD was reported in another retrospective study 
of 32 PLAO women with multiple fractures treated 
with teriparatide for 12 months, with greater BMD in-
creases in the teriparatide group compared to controls 
(15.5% ± 6.6 vs 7.5% ± 7.1, P = 0.02) (130).
Idiopathic osteoporosis. RCTs are missing with re-
gard to the treatment of premenopausal idiopathic 
osteoporosis. Teriparatide has been used, as previously 
reviewed, in a small sample of women with this disorder 
(17). The latest study using teriparatide included ana-
lyses of bone biopsies and the expression of the IGF-1 
receptor (IGF-1R) on circulating osteoblast progenitor 
(COP) among peripheral blood mononuclear cells 
(PBMCs) (131). In 11 premenopausal women treated 
with teriparatide for 24  months, a BMD increase of 
2.9 ± 5.7% at the spine and a 6.9 ± 4.6% increase at 
the FN were reported (131). This study showed that 
the percentage COP cells and IGF-1R expression on 
COP cells reflected tissue level bone formation (131). 
Thus, the authors proposed that the amount of IGF-1R 
on COP cells may reflect IGF-1 resistance downstream 
from the IGF-1R in premenopausal idiopathic osteopor-
osis. This new study is in line with previous studies that 
suggested an IGF-1 resistance in premenopausal idio-
pathic osteoporosis (132).
Possible Teratogenic Effects of  
Anti-Osteoporotic Drugs
Treatment of premenopausal women should always take 
into consideration the potential teratogenic effects of the 
drug during pregnancy. Although a toxic effect in preg-
nant rats after exposure to bisphosphonates has been 
described (133), the majority of the literature regarding 
bisphosphonate use in humans does not report severe 
adverse fetal and maternal events (134). Nevertheless, a 
few reports regarding shortened gestational age, lower 
neonatal birth weight and transient hypocalcemia in the 
newborns and very rare cases of spontaneous abortions 
and congenital anomalies have been published (135-
137). These studies, however, do not include controls or 
the reasons for bisphosphonate treatment.
In 2018, data were published from the French 
Reference Centre of Teratogenic Agents which included 
women who received bisphosphonates in the 6 weeks 
before or during pregnancy and had systemic (n = 23) 
or bone diseases (n = 13) (138). This paper reported the 
reasons for bisphosphonate treatment and included con-
trol groups. The most frequent cause for bisphosphonate 
treatment was a rheumatologic disease (for which also 
concomitant drugs were prescribed), and these pa-
tients were compared to women with the same diseases 
without bisphosphonate exposure. In patients exposed 
to bisphosphonates due to systemic diseases, therapeutic 
terminations of pregnancies were higher compared to 
controls (4/23 [17.4%] vs 1/92 [1.1%], P = 0.006). No 
difference in the rate of congenital malformations was 
reported, but the rate of neonatal complications was 
higher for cases than controls (4/16 [25.0%] vs 4/64 
[6.3%] P = 0.027). Neonatal complications included 
cardiac arrhythmias (n = 1), maternal-fetal infection 
(n = 1), acute fetal distress (n = 1), and polycythemia and 
thrombocytopenia (n = 1). Considering women without 
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any systemic disease who received bisphosphonates 
for primary nonmalignant bone diseases (bone disease 
group), the live birth rate was lower compared to healthy 
controls (8/10 [80%] vs 50/50 [100%], P = 0.025). No 
congenital malformations were reported in either group; 
however, fetopathological examinations were not per-
formed. It might be possible that the complications re-
ported were mainly due to the severity of the underlying 
diseases and other concomitant medication; however, a 
severity index for the diseases was not reported. The au-
thors stated that the expected rate of spontaneous abor-
tion is approximatively 12% in the general population 
in France; thus, using the healthy control group as a 
comparison for the “bone disease” group without spon-
taneous abortions might not be appropriate. Further 
studies are needed to clarify this issue. As a measure of 
safety, it has been proposed that bisphosphonate treat-
ment should not be initiated if a woman is planning a 
pregnancy in the next 12 months (16).
There are no human case reports on the fetal effects 
of teriparatide or denosumab in pregnant women. In 
cynomolgus monkeys, who were exposed to denosumab 
in utero, the following persistent congenital defects 
were reported: dental dysplasia, decreased bone length, 
reduced cortical thickness, and decreased peak load and 
ultimate strength at the femur diaphysis, while others 
bone features that resembled an osteoporotic phenotype 
appeared partially reversible (139).
Hence, both denosumab and teriparatide are contra-
indicated in pregnant women; this recommendation is 
based on the lack of studies in pregnant women.
Conclusions
Underlying diseases are common among premeno-
pausal women with osteoporosis. The diagnosis of 
osteoporosis in premenopausal women requires not 
only the presence of low BMD but also evidence 
of bone fragility, which reflects an abnormal bone 
microarchitecture. In contrast to postmenopausal 
women, however, bone turnover is not necessarily 
elevated in premenopausal osteoporosis, at least not 
when estrogen deficiency is absent. In the rare cases of 
idiopathic osteoporosis, new evidence from HR-pQCT 
and genetic evaluations suggest that the primary def-
icit is in the osteoblast function, but the exact mech-
anisms remains unknown. Identifying premenopausal 
women at risk of fracture remains challenging, and 
further HR-pQCT studies may contribute to under-
stand the importance of bone microstructural alter-
ations in this population, although the clinical use 
of this technology remains uncertain. Moreover, we 
need additional research to establish normative data-
bases for premenopausal women, so that in the future, 
HR-pQCT will be more useful clinically. Meanwhile, 
DXA with vertebral fracture assessment, common 
clinical risk factors, and disease- and drug-related risk 
factors (in case of secondary osteoporosis) must all be 
taken into account to properly assess fracture risk in 
these women, as recently illustrated in diabetes (47).
The treatment of underlying causes of secondary 
osteoporosis is beneficial not only with regards to BMD 
but also to bone microstructure. In case treatment of 
the underlying cause is not successful and/or in presence 
of severe osteoporosis, antiresorptive and bone-forming 
drugs can be used as in postmenopausal osteoporosis. 
Further RCTs with fracture reduction as a primary out-
come are needed to better tailor treatment to patients 
at high risk of fracture. Although some new data on 
bisphosphonate safety in women at childbearing poten-
tial are now available, more robust evidence is needed 
as well as data on denosumab and bone-forming drugs 
like teriparatide, abaloparatide, and romosozumab 
in humans.
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